Transdermal selegiline

Drugs of Today

Volumn 43, Issue 6, 2007, Pages 361-377

  Patkar, Ashwin A ^a,d   Pae, Chi Un ^a,b   Zarzar, Michael ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The Catholic University of Korea   (South Korea)

^c Glenwood Psychiatric Associates   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINE OXIDASE (FLAVIN CONTAINING); CARBAMAZEPINE; LEVOTHYROXINE; PHENYLPROPANOLAMINE; PLACEBO; PSEUDOEPHEDRINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TYRAMINE; WARFARIN;

APPLICATION SITE IRRITATION; APPLICATION SITE REACTION; ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DIET; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EXPERIENCE; HUMAN; HYPERTENSIVE CRISIS; INSOMNIA; MAJOR DEPRESSION; MULTIPLE CYCLE TREATMENT; ORTHOSTATIC HYPOTENSION; PRURITUS; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; TOBACCO DEPENDENCE; TREATMENT INDICATION; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SELEGILINE;

EID: 34547814195     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.6.1050794     Document Type: Review

References (84)

1. Robinson, D.S. Monoamine oxidase inhibitors: A new generation. Psychopharmacol Bull 2002, 36: 124-38.
2. Ban, T.A. Pharmacotherapy of depression: A historical analysis. J Neural Transm 2001, 108: 707-16.
3. Amsterdam, J., Chopra, M. Monoamine oxidase inhibitors revisited. Psychiatric Ann 2001, 31: 361-70.
4. Asatoor, A.M., Levi, A.J., Milne, M.D. Tranyl-cypromine and cheese. Lancet 1963, 54: 733-4.
5. Stafford, R.S., MacDonald, E.A., Finkelstein, S.N. National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 2001, 3: 232-5.
6. Johnson, A.G. Monoamine oxidase inhibitors. Br Med J 1968, 2: 433.
7. Billett, E.E. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicol 2004, 25: 139-48.
8. Yamada, M., Yasuhara, H. Clinical pharmacology of MAO inhibitors: Safety and future. Neurotoxicology 2004, 25: 215-21.
9. Mawhinney, M., Cole, D., Azzaro, A.J. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003, 55: 27-34.
10. Lotufo-Neto, F., Trivedi, M., Thase, M.E. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacol 1999, 20: 226-47.
11. Riederer, P., Youdim, M.B. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with I-deprenyl. J Neurochem 1986, 46: 1359-65.
12. Glover, V., Reveley, M.A., Sandler, M. A monoamine oxidase inhibitor in human urine. Biochem Pharmacol 1980, 29: 467-70.
13. Birkmayer, W., Knoll, J., Riederer, P., Youdim, M.B. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 1983, 19: 170-6.
14. Tetrud, J.W., Langston, J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989, 245: 519-22.
15. Youdim, M.B., Riederer, P.F. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 2004, 63: S32-5.
16. Thase, M.E., Trivedi, M.H., Rush, A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacol 1995, 12: 185-219.
17. Barrett, J.S., Rohatagi, S., DeWitt, K.E., Morales, R.J., DiSanto, A.R. The effect of dosing regimen and food on the bioavailability of the extensively metabolized, highly variable drug Eldepryl® (selegiline hydrochloride). Am J Ther 1996, 3: 298-313.
18. Rohatagi, S., Barrett, J.S., DeWitt, K.E., Lessard, D., Morales, R.J. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. Biopharm Drug Dispos 1997, 18: 665-80.
19. Wecker, L., James, S., Copeland, N., Pacheco, M.A. Transdermal selegiline: Targeted effects on monoamine oxidases in the brain. Biol Psychiatry 2003, 54: 1099-104.
20. Mann, J.J., Aarons, S.F., Wilner, P.J. et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989, 46: 45-50.
21. McGrath, P.J., Stewart, J.W., Harrison, W., Wager, S., Nunes, E.N., Quitkin, F.M. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull 1989, 25: 63-7.
22. Sunderland, T., Cohen, R.M., Molchan, S. et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994, 51: 607-15.
23. Bodkin, J., Kwon, A. Selegiline and other atypical MAO inhibitors in depression. Ann Psychiatry 2001, 31: 385-91.
24. Clarke, A., Brewer, F., Johnson, E.S. et al. A new formulation of selegiline: Improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003, 110: 1241-55.
25. Ricaurte, G.A., Langston, J.W., DeLanney, L.E., Irwin, I., Brooks, J.D. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 1985, 59: 259-64.
26. Wilkosz, M.F., Bogner, R.H. Transdermal drug delivery. Part 1: Current status. U.S. Pharmacist. 2003; 28. Available at: http://www.uspharmacist. com/index.asp?show=article&page=8_1061.htm.
27. EMSAM® selegiline transdermal system new drug application 21,336/21,708. Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4186B2_01_01_Somerset- EMSAM.pdf.
28. Krishnan R. Advances in psychopharmacology: MAOIs. Scientific report session. American Psychiatric Association, New York, 2004.
29. Cadet, J.L., Ladenheim, B., Baum, I., Carlson, E., Epstein, C. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res 1994, 655: 259-62.
30. Wagner, G.C., Jarvis, M.F. Evaluation of the pharmacological similarities between phenyl-propanolamine and amphetamine: Effects on schedule-controlled behavior. Synapse 1990, 6: 101-5.
31. Barrett, J.S., DiSanto, A.R., Thomford, P.J., Larsen, E.M., Palazzolo, M.J., Morales, R.J. Toxicokinetic evaluation of a selegiline transdermal system in the dog. Biopharm Drug Dispos 1997, 18: 165-84.
32. Gordon, M.N., Muller, C.D., Sherman, K.A., Morgan, D.G., Azzaro, A.J., Wecker, L. Oral versus transdermal selegiline: Antidepressant-like activity in rats. Pharmacol Biochem Behav 1999, 63: 501-6.
33. Robinson, D.S., Campbell, I.C., Walker, M., Statham, N.J., Lovenberg, W., Murphy, D.L. Effects of chronic monoamine oxidase inhibitor treatment on biogenic amine metabolism in rat brain. Neuropharmacol 1979, 18: 771-6.
34. Campbell, I.C., Shiling, D.J., Upper, S., Slater, S., Murphy, D.L. A biochemical measure of monoamine oxidase type A and B inhibitor effects in man. J Psychiatr Res 1979, 15: 77-84.
35. Cesura, A.M., Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992, 38: 171-297.
36. Magyar, K., Palfi, M., Tabi, T., Kalasz, H., Szende, B., Szoko, E. Pharmacological aspects of (-)-deprenyl. Curr Med Chem 2004, 11: 2017-31.
37. Khanzode, S.D., Dakhale, G.N., Khanzode, S.S., Saoji, A., Palasodkar, R. Oxidative damage and major depression: The potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003, 8: 365-70.
38. Heinonen, E.H., Rinne, U.K. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand Suppl 1989, 126: 103-11.
39. Berry, M.D. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem 2004, 90: 257-71.
40. Sabelli, H., Fink, P., Fawcett, J., Tom, C. Sustained antidepressant effect of PEA replacement. J Neuropsychiatry Clin Neurosci 1996, 8: 168-71.
41. Bodkin, J.A., Amsterdam, J.D. Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002, 159: 1869-75.
42. Guelfi, J.D., Strub, N., Loft, H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord 2000, 58: 201-9.
43. Feiger, A.D., Rickels, K., Rynn, M.A., Zimbroff, D.L., Robinson, D.S. Selegiline transdermal system for the treatment of major depressive disorder: An 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006, 67: 1354-61.
44. Data on file, Somerset Pharmaceuticals and Bristol-Myers Squibb Pharmaceuticals. 45. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000, 157 (4 Suppl.): 1-45.
45. Amsterdam, J.D. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003, 64: 208-14.
46. Amsterdam, J.D., Bodkin, J.A. Selegiline transdermal system in the prevention of relapse of major depressive disorder: A 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006, 26: 579-86.
47. Moonsammy, G., Blob, L.F., Sharoky, M., VanDenBerg, C.M., Azzaro, A.J. Safety of selegiline transdermal system in long-term prevention of relapse of depression. Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton 2003.
48. Anderson, M.C., Hasan, F., McCrodden, J.M., Tipton, K.F. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res 1993, 18: 1145-9.
49. Blackwell, B., Marley, E., Price, J., Taylor, D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967, 113: 349-65.
50. Da Prada, M., Kettler, R., Cesura, A.M., Richards, J.G. Reversible, enzyme-activated monoamine oxidase inhibitors: New advances. Pharmacol Res Commun 1988, 20 (Suppl. 4): 21-33.
51. Brown, C.S., Bryant, S.G. Monoamine oxidase inhibitors: Safety and efficacy issues. Drug Intell Clin Pharm 1988, 22: 232-5.
52. McCabe, B.J. Dietary tyramine and other pressor amines in MAOI regimens: A review. J Am Diet Assoc 1986, 86: 1059-64.
53. Azzaro, A.J., VanDenBerg, C.M., Blob, L.F. et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol 2006, 46: 933-44.
54. Barrett, J.S., Hochadel, T.J., Morales, R.J. et al. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. J Clin Pharmacol 1997, 37: 238-47.
55. Walker, S.E., Shulman, K.I., Tailor, S.A., Gardner, D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol 1996, 16: 383-8.
56. Berlin, I., Zimmer, R., Cournot, A., Payan, C., Pedarriosse, A.M., Puech, A.J. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther 1989, 46: 344-51.
57. Simpson, G.M., Gratz, S.S. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther 1992, 52: 286-91.
58. 2/20 mg selegiline transdermal system (STS) in healthy male volunteers. Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton 2000.
59. EMSAM® prescribing information. Available at: http://www.bms.com/cgi-bin/anybin.pl?sql= select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=112&key=PPI.
60. Data on file, Somerset Pharmaceuticals, presented to FDA Advisory Committee, October 26, 2005.
61. Sternbach, H. The serotonin syndrome. Am J Psychiatry 1991, 148: 705-13.
62. Heinonen, E., Myllyla, V. Autonomic effects of selegiline: Possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998, 65: 280-2.
63. Neuvonen, P. Current hazardous drug interactions. Duodecim 1993, 109: 1833-9.
64. Hilton, S.E., Maradit, H., Moller, H.J. Serotonin syndrome and drug combinations: Focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci 1997, 247: 113-9.
65. Nierenberg, D.W., Semprebon, M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993, 53: 84-8.
66. Richard, I.H., Kurlan, R. A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 1997, 49: 1168-70.
67. Nierenberg, A.A., Keck, P.E. Jr. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. J Clin Psychopharmacol 1989, 9: 42-5.
68. Novick, J.S., Stewart, J.W., Wisniewski, S.R. et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: Preliminary findings from STAR*D. J Clin Psychiatry 2005, 66: 1002-11.
69. Henkel, V., Mergl, R., Allgaier, A.K., Kohnen, R., Moller, H.J., Hegerl, U. Treatment of depression with atypical features: A meta-analytic approach. Psychiatry Res 2006, 141: 89-101.
70. McGrath, P.J., Stewart, J.W., Janal, M.N., Petkova, E., Quitkin, F.M., Klein, D.F. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000, 157: 344-50.
71. Trivedi, M.H., Fava, M., Wisniewski, S.R. et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354: 1243-52.
72. Thase, M.E., Rush, A.J. Treatment-resistant depression. In: Bloom, F.E., Kupfer, D.J. (Eds.). Psychopharmacology. The Fourth Generation of Progress. Raven, New York, pp 1081-97.
73. Anderson, I.M., Nutt, D.J., Deakin, J.F. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000, 14: 3-20.
74. Amsterdam, J.D., Shults, J. MAOI efficacy and safety in advanced stage treatment-resistant depression - A retrospective study. J Affect Disord 2005, 89: 183-8.
75. Thase, M.E., Frank, E., Mallinger, A.G., Hamer, T., Kupfer, D.J. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992, 53: 5-11.
76. Nolen, W.A., van de Putte, J.J., Dijken, W.A. et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988, 78: 676-83.
77. Quitkin, F.M., Stewart, J.W., McGrath, P.J. et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993, Suppl., 30-4.
78. Mohammadi, M.R., Ghanizadeh, A., Alaghband-Rad, J., Tehranidoost, M., Mesgarpour, B., Soori, H. Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial. J Child Adolesc Psychopharmacol 2004, 14: 418-25.
79. Mechcatie, E. Transdermal MAO inhibitor patch effective for ADHD. Clinical Psychiatry News 2003, 31: 18.
80. Houtsmuller, E.J., Notes, L.D., Newton, T. et al. Transdermal selegiline and intravenous cocaine: Safety and interactions. Psychopharmacology (Berl) 2004, 172: 31-40.
81. Bartzokis, G., Beckson, M., Newton, T. et al. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacol 1999, 20: 582-90.
82. Biberman, R., Neumann, R., Katzir, I., Gerber, Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with pla cebo plus nicotine skin patch for smoking cessation. Addiction 2003, 98: 1403-7.
83. George, T.P., Vessicchio, J.C., Termine, A., Jatlow, P.I., Kosten, T.R., O'Malley, S.S. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003, 53: 136-43.
84. Fiedorowicz, J.G., Swartz, K.L. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 2004, 10: 239-48.